Exuberil Captures Market Share Gains Following Time & CNN Report on Ineffectiveness of Antidepressant Drugs

Share Article

Third quarter sales of Pharmaxa Labs best-selling, all-natural, anti-anxiety and antidepressant supplement, Exuberil, are surging. The company is enjoying strong market gains, purred by the publication of an early June CNN/Time report citing findings from a January publication by the Journal of the American Medical Association (JAMA) regarding the dangers and ineffectiveness of many prescription antidepressants.

Pharmaxa Labs - the makers of one of the best-selling, all-natural, anti-anxiety and antidepressant supplements, Exuberil - has captured a large market gain during the third quarter of this year. Sales have been spurred by a landmark Time and CNN report informing the public of the dangers and ineffectiveness that are associated with many popular prescription antidepressants.

A startling early June report that was published by Time Magazine online (in partnership with CNN) entitled, "Antidepressants: Are They Effective or Just a Placebo?," has stirred up a pot of consumer awareness as to the effectiveness, as well as the risks, that could be associated with using many of the popularly prescribed antidepressant drugs. The news report made headlines across the country, as more people were made aware of a groundbreaking study that the report cited - from the American Medical Association (JAMA), and the Food and Drug Administration (FDA) - which purports that there are many risks and side effects of prescription antidepressants that most people are entirely unaware of.

Of the numerous and now known risks, the report said that, "In the early 1990s, everyone was listening to Prozac -- right up until they weren't anymore. By the middle of that decade, the media had begun spotlighting disasters involving the life-changing wonder drug -- cases of suicide, even mass murder, apparently spurred by Prozac and similar medications. And by 2005, the Food and Drug Administration had mandated a black-box warning on all antidepressants, cautioning against an increase in suicide risk in certain patients."

The health report went on to highlight findings from an American Medical Association (JAMA) paper that was published at the beginning of this year. "Since then, a small but vocal minority of researchers have also questioned whether the mood-enhancing benefit of antidepressants amounts to anything more than a psychological artifact. They point to studies that suggest the drugs' seemingly powerful effects are the same as those of a sugar pill. Most recently, a headline-grabbing Journal of the American Medical Association (JAMA) paper published in January found that antidepressants worked no better than a placebo in patients with mild or moderate depression (but the study did conclude that medication helped the most persistent and severe cases). For some observers, however, the judgment was sealed. That month, Newsweek ran a cover story bemoaning "The Depressing News About Antidepressants."

Tom Whitman, the spokesperson for Exuberil, offers some insight as to why their supplement has enjoyed such vast market gains during the third quarter of this year, riding on the heels of groundbreaking news headlines, such as the aforementioned health report and study.

"The reality is that there are risks attached to using prescription antidepressants, and that they may not be for everyone…as this health report and study highlights," Whitman says.

As to why Exuberil has enjoyed strong growth during the third quarter, the answer is one that comes easy for Whitman. "We offer an all-natural alternative for consumers that are seeking effective relief from depression and anxiety," Whitman explains.

Whitman further emphasizes, "But, unlike some of the prescribed drugs that are out there, our supplement (Exuberil) does not cause any side effects, and has been proven to--and currently is--providing vast relief to countless people from all over the world!"

Exuberil is an all-natural supplement intended for treating depression and anxiety that is taken orally, once per day.

It utilizes Suntheanine--the main active ingredient in Exuberil--which has been extensively researched and documented as being beneficial in significantly reducing physical, mental and social symptoms of depression, anxiety, insomnia, and irritability.

Exuberil also incorporates 5-HTP, Valerian, and Kava Kava--all which have been proven to significantly improve the symptoms of depression, and to reduce anxiety and stress.

Exuberil does not contain ingredients that will induce lack of REM (rapid eye movement during sleep cycles), which are common side effects of the many prescribed antidepressants and anti-anxiety drugs that are currently on the market.

There are currently no documented or known, adverse side effects associated with taking Exuberil.

Most users will feel noticeable results from taking Exuberil within the first four to six weeks of usage, when used as directed.

You can learn more by visiting: http://www.Exuberil.com.

About Exuberil:

  •     Developed by Pharmaxa Labs--a leading nutraceutical company
  •     Exuberil's proprietary blend of ingredients are 100% natural GMP certified
  •     Contains Suntheanine--the main active ingredient in Exuberil--which has been extensively researched and documented as being beneficial in significantly reducing physical, mental and social symptoms of depression, anxiety, insomnia, and irritability
  •     Incorporates 5-HTP, Valerian, and Kava Kava, which have been proven to significantly improve symptoms of depression and reduce anxiety
  •     Does not contain ingredients that will induce lack of REM (rapid eye movement during sleep cycles)
  •     Non habit-forming; no withdrawal symptoms after cessation of usage
  •     100% safe, effective and all-natural
  •     Visit them online for generous discounts off retail pricing and to learn more at: http://www.Exuberil.com
  •     Source: Internet, 2010; http://www.time.com/time/health/article/0,8599,1991841,00.html?xid=rss-topstories

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Liz Gilman
Visit website